Aspects of molecular medicine最新文献

{"title":"Identification and exploration of novel FGFR-1 inhibitors in the Lotus database for Cholangiocarcinoma (CCA) treatment","authors":"Samuel Aduramurewa Osunnaya ,&nbsp;Wilberforce K. Ndarawit ,&nbsp;Ifeoluwa Aderibigbe ,&nbsp;Ibilola A. Omolopo ,&nbsp;Precious O. Aribisala ,&nbsp;Ayodele Oluwasegun Elekan ,&nbsp;Adeola Sakirat Adeyemo ,&nbsp;Sheriffdeen Abiola Amoo ,&nbsp;Olatunde Simbiat Olamiposi ,&nbsp;Njogu M. Kimani ,&nbsp;Taiwo Hamidat Olaide ,&nbsp;Adedoyin John-Joy Owolade ,&nbsp;Damilola Samuel Bodun","doi":"10.1016/j.amolm.2025.100085","DOIUrl":"10.1016/j.amolm.2025.100085","url":null,"abstract":"<div><div>Cholangiocarcinoma (CCA) is a rare but aggressive cancer affecting the bile duct, with limited treatment options and a poor prognosis. This study employed a machine learning algorithm and molecular docking using Maestro to screen 215,925 compounds from the Lotus database, aiming to identify potential fibroblast growth factor receptor-1 (FGFR1) inhibitors as therapeutic agents. Five promising compounds were identified, with binding energies ranging from −10.018 to −8.439 kcal/mol, all outperforming the standard drug Dovitinib (−8.419 kcal/mol). Molecular mechanics calculations and MM/GBSA analysis confirmed the structural stability and favorable binding energies of the protein-ligand complexes. Additionally, 100-ns molecular dynamic simulations demonstrated that the top three compounds remained stable within FGFR1's active site, supported by root mean square deviation, root mean square fluctuation, and hydrogen bond interactions. Overall, these five compounds show promise as potential therapeutic agents for CCA and warrant further investigation for drug development.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100085"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stimuli-responsive supramolecular hydrogels for paclitaxel delivery: Progress and prospects","authors":"Mohammad Qutub ,&nbsp;Amol Tatode ,&nbsp;Jayshree Taksande ,&nbsp;Tanvi Premchandani ,&nbsp;Milind Umekar ,&nbsp;Ujban Md Hussain ,&nbsp;Dinesh Biyani ,&nbsp;Dadaso Mane","doi":"10.1016/j.amolm.2024.100062","DOIUrl":"10.1016/j.amolm.2024.100062","url":null,"abstract":"<div><div>Cancer remains a leading cause of death worldwide, while chemotherapy playing a pivotal role in its management. However, traditional chemotherapy often encounters challenges such as non-specific drug delivery, systemic toxicity, and rapid clearance. Thermosensitive supramolecular hydrogels have emerged as an innovative platform for localized and sustained drug delivery, particularly for paclitaxel (PTX), a potent chemotherapeutic agent. These hydrogels exhibit unique sol-gel phase transitions at physiological temperatures, enabling minimally invasive administration and prolonged retention at tumor sites. Advances in hydrogel formulations, including dual stimuli-responsive systems and nanocrystal-loaded designs, enhance drug stability, controlled release, and therapeutic efficacy. Additionally, these hydrogels can incorporate multimodal therapeutic agents, such as immunomodulators and photosensitizers, achieving synergistic anticancer effects. Despite significant progress, challenges remain in optimizing tumor penetration, scaling production, and addressing tumor heterogeneity. Ongoing research into hydrogel composition, biocompatibility, and targeted delivery mechanisms aims to overcome these limitations, paving the way for their clinical translation. This review highlights recent advancements and future prospects of thermosensitive hydrogels for PTX delivery, emphasizing their potential to revolutionize cancer treatment by reducing systemic toxicity and improving localized therapeutic outcomes.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100062"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure-based insights into fatty acid modulation of lipid-sensing nuclear receptors PPARδ/γ for glycemic regulation","authors":"Shankar Gharge ,&nbsp;Charushila V. Balikai ,&nbsp;Sachin Gudasi","doi":"10.1016/j.amolm.2025.100079","DOIUrl":"10.1016/j.amolm.2025.100079","url":null,"abstract":"<div><div>This study explores the therapeutic potential of fatty acids (FA1-FA12) in the treatment of diabetes mellitus, focusing on their modulation of lipid-sensing nuclear receptors PPARδ/γ. Network pharmacology analysis highlighted key pathways involved in diabetes, including PI3K-Akt, MAPK, and insulin signaling, with targets such as PPAR, INSR, SLC2A4, and AKT1, suggesting a multi-target approach to disease modulation. To investigate their mechanism of action, a pharmacophore model was developed based on the PPAR-γ inhibitor Pioglitazone, offering insights into the essential structural features for ligand binding. Molecular docking studies revealed that FA1 and FA2 exhibited favorable binding affinities at the active sites of both PPAR-γ and PPAR-δ and MD trajectory analysis to evaluate binding orientation and stability of the molecules and the energy profiles of the molecules FA1 (Palmitic acid) and FA2 (Myristic acid), both in complex with the both PPAR-γ and PPAR-δ protein, were assessed. Additionally, computational analyses, including DFT and ADMET predictions, provided valuable information on the electronic and physicochemical properties of the fatty acids. Although these compounds displayed promising lipophilicity and permeability, their poor aqueous solubility indicates the need for optimization in drug development. Overall, this study lays a foundation for the exploration of fatty acids as potential therapeutic agents for diabetes, particularly through their modulation of PPARδ/γ activity for glycemic regulation.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100079"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statin therapy for NAFLD: Molecular underpinnings of myopathic consequences and treatment strategies","authors":"Pratiksha Nanepag ,&nbsp;Shubhada Mangrulkar ,&nbsp;Aarti Shriwas ,&nbsp;Mayur Kale ,&nbsp;Sapana Kushwaha ,&nbsp;Nitu Wankhede ,&nbsp;Brijesh Taksande ,&nbsp;Milind Umekar","doi":"10.1016/j.amolm.2025.100091","DOIUrl":"10.1016/j.amolm.2025.100091","url":null,"abstract":"<div><div>Non-alcoholic fatty liver disease (NAFLD) encompasses a range of hepatic disorders characterized by excessive lipid accumulation in hepatocytes and is closely linked to metabolic syndrome. Statins, which are potent lipid-lowering agents, have emerged as potential therapeutic options for managing NAFLD. Recent meta-analyses have demonstrated the efficacy of statins in reducing liver enzymes, improving histological features, and attenuating disease progression in patients with NAFLD. Mechanistically, statins exert their beneficial effects by inhibiting cholesterol synthesis, modulating lipid metabolism, and exhibiting anti-inflammatory and antifibrotic properties. They target key pathogenic pathways in NAFLD, including the inhibition of sterol regulatory element-binding proteins (SREBPs), activation of peroxisome proliferator-activated receptor-alpha (PPAR-α), and enhancement of fatty acid β-oxidation. Additionally, statins mitigate hepatic inflammation by reducing pro-inflammatory cytokines and oxidative stress, while promoting fibrosis regression through the inhibition of RhoA/Rho kinase signaling and transforming growth factor-beta (TGF-β) pathways. However, statin-associated muscle symptoms (SAMS) remain a significant concern, often leading to treatment non-adherence or discontinuation. The molecular mechanisms underlying statin-induced myopathy involve the inhibition of the mevalonate pathway, coenzyme Q10 depletion, mitochondrial dysfunction, and disruption of the ubiquitin-proteasome system. Strategies to prevent and manage SAMS include alternative dosing regimens, statin switching, and the use of complementary therapies such as coenzyme Q10 and vitamin D supplementation. Novel approaches, including PCSK9 inhibitors and nutraceuticals, have also shown promise in mitigating statin-related muscle adverse effects. In conclusion, statins offer a promising therapeutic avenue for NAFLD management, particularly in patients with elevated cardiovascular risk. This review updated the statins' therapeutic potential in NAFLD, their molecular mechanisms, statin-induced myopathy, extra-hepatic effects, and preventive strategies for future research.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized approaches to lung cancer treatment: A review of targeted therapies, pharmacogenomics, and combination strategies","authors":"Namini M,&nbsp;Bhagya G,&nbsp;Manjari Sharma","doi":"10.1016/j.amolm.2025.100073","DOIUrl":"10.1016/j.amolm.2025.100073","url":null,"abstract":"<div><div>Globally, lung cancer—more specifically, non-small cell lung cancer (NSCLC)—contributes significantly to the death toll from cancer. Recent advances in molecular research have identified key genetic mutations that drive tumor growth, including those in the EGFR, KRAS, ALK, and MET genes, accounting for around 80 % of lung cancers that are categorized as non-small cell lung cancer (NSCLC). The advent of targeted therapies such as Tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have revolutionized cancer treatment by specifically inhibiting oncogenic pathway. However, despite this advancements, treatment outcomes remain suboptimal due to intrinsic heterogeneity of cancers and the development of resistance mechanisms. The cancer treatment landscape is constantly changing to address these challenges and improve patient outcomes. Customization of cancer therapies through pharmacogenomics is hindered by tumor adapatability and resistance, limited prognostic biomarkers and suboptimal monotherapies, necessitating innovative research in adoptive therapies biomarker development and combination therapies. Ongoing trails aims to enhance treatment endurance via the advancement of combination regimens incorporating multiple targeted therapies or synergistic combination immunotherapy with chemotherapy. Ongoing research is focused on optimizing CRISPR-Cas9 delivery system, improving specificity and minimizing half target effect. Emphasizes the crucial role of molecular mutations, the advantages and disadvantages of targeted medicines, and the prospects for enhancing the effectiveness of lung cancer treatment results are all highlighted in this Review.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100073"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of pathogenic genetic variants associated with familial hypercholesterolemia in Ghanaian children","authors":"Philip Opoku-Agyeman ,&nbsp;Prince Ameyaw ,&nbsp;Selassie Bruku ,&nbsp;Gideon Ofori Addo ,&nbsp;Gideon Tetteh ,&nbsp;Esther Baafi ,&nbsp;Sandra Korkor Asare ,&nbsp;Abigail Foriwaah Frimpong ,&nbsp;Samuel Adu-Poku ,&nbsp;Sena Adzoa Matrevi ,&nbsp;Nancy Odurowah Duah-Quashie ,&nbsp;Kwesi Z. Tandoh","doi":"10.1016/j.amolm.2025.100067","DOIUrl":"10.1016/j.amolm.2025.100067","url":null,"abstract":"<div><div>Familial hypercholesterolemia (FH) is an important contributor to atherosclerotic cardiovascular disease (ASCVD) burden globally. FH disrupts cholesterol metabolism and causes lifelong elevation in low-density lipoprotein cholesterol (LDL-C). In sub-Saharan Africa (SSA), the increasing burden of ASCVD may be partly driven by genetic dyslipidemias of which FH is the commonest. However, there is absence of data on FH prevalence in SSA which delineates an important gap in the management of ASCVD. This study is the first to investigate the prevalence of pathogenic variants associated with FH in Ghana. We used 96 deidentified archived dried blood spot samples collected from a Ghanaian cohort, to determine the prevalence of pathogenic genetic variants associated with FH. These samples were collected from children under 9 years old as part of surveillance for antimalarial drug resistance in 2021. We searched the NCBI's ClinVar database and used <em>in silico</em> tools to identify 500–800 nucleotide base pair regions of interest in 3 genes known to harbor the commonest genetic variants associated with FH. We selected these regions of interest from the <em>LDLR</em> gene exons 4, 9 and 10, <em>APOB</em> exon 26 and <em>PCSK9</em> exon 2 loci. Next, we amplified these regions of interest using conventional polymerase chain reaction. Finally, we sequenced the amplicons using paired-end Sanger sequencing and called variants from the chromatogram files using an in-house custom built bash script utilizing the open access program Tracy. Subsequently, we did quality checks on all reported pathogenic variant calls manually using Benchling's sequence alignment tool. We identified one pathogenic variant V523 M in the <em>LDLR</em> exon 10 region and report an FH prevalence of 1% (1/96), 95% CI: [0%,3.07%], in our Ghanaian cohort. Our finding underscores the importance of FH in driving ASCVD burden in Ghana and advocates the need for implementation science-driven programs to manage this genetic dyslipidemia in Ghana and SSA.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100067"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetoplastid diseases: Insights into the mechanisms of drug action and resistance for novel drug discovery","authors":"Abdullah M. Tauheed ,&nbsp;Ammar U. Danazumi ,&nbsp;Oluwafemi A. Adepoju ,&nbsp;Patricia I. Kobo ,&nbsp;Auwal Adamu ,&nbsp;Emmanuel O. Balogun","doi":"10.1016/j.amolm.2025.100071","DOIUrl":"10.1016/j.amolm.2025.100071","url":null,"abstract":"<div><div><em>Trypanosoma</em> and <em>Leishmania</em> species are kinetoplastid protozoan parasites that cause diseases which result in significant disability-adjusted life years (DALYs) and agricultural losses in the developing world. Despite the progress recorded in understanding biology and chemotherapy of these pathogens of neglected diseases, treatment failure, due to drug resistance or toxicity-driven non-compliance remain major challenges. Advances in molecular parasitology have led to the identification of specific transport mechanisms, druggable targets and persister-like cells, which play distinct roles in the overall success of therapies. Transporters and other cellular transport mechanisms affect the internalisation of drugs and their intracellular availability which determine drug activity. Thus, we reviewed kinetoplastid drug transport mechanisms, molecular drug targets and persisters to highlight mechanisms of action and development of resistance for antikinetoplastid drugs, with the aim of providing novel insights for drug discovery programmes.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100071"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic potential of monocyte subsets, TNF-α, and IL-6 in pediatric celiac disease: A case-control study","authors":"Naglaa Makram Farag ,&nbsp;Noura Elbakry ,&nbsp;Mahmoud Mousa ,&nbsp;Mohamed S. Hemeda ,&nbsp;Zamzam Hassan Mohamed","doi":"10.1016/j.amolm.2025.100083","DOIUrl":"10.1016/j.amolm.2025.100083","url":null,"abstract":"<div><div>Celiac disease (CD) is a chronic autoimmune disorder of the small intestine, which is triggered by dietary gluten, especially in individuals with a genetic instinct. Monocytes play an important role in modifying intestinal immunity and inflammation, yet the importance of their subgroups in CD is not clear.</div></div><div><h3>Methods</h3><div>The case-control study was held at the Pediatric Outpatient Clinic of Minia University Hospital, including 57 CD patients and 29 age- and sex-matched healthy controls. Clinical examination, laboratory check, and history were demonstrated for all participants. The serum levels of the IL-6 and TNF-α cytokines were measured using ELISA, and most analysis was done using flow cytometry. The variable with significant differences was further evaluated for its clinical ability.</div></div><div><h3>Results</h3><div>Monocytes are more prevalent in CD patients than in controls. In the case group, the average level of monocyte CD14+/CD16+ and CD14–/CD16+ was much higher than in the control group of CD patients (P-value &lt;0.001). Additionally, CD patients who tested positive for antibodies had much higher levels of certain monocyte types compared to those who tested negative (p-values of 0.003, 0.011, and 0.001, respectively). Cytokines were not balanced, as levels of TNF-α and IL-6 were much higher in CD patients than in the control group. There was a significant positive relationship (p-value &lt;0.001) between different types of monocytes and the amounts of autoantibodies, TNF-α, and IL-6.</div></div><div><h3>Conclusion</h3><div>TNF-α, IL-6, and certain types of monocytes could be useful indicators for diagnosing CD, as we found important differences between the groups we studied.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100083"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In silico identification of potential inhibitors for the universal stress G4LZI3 protein from Schistosoma mansoni using molecular docking and molecular dynamics simulation analyses","authors":"Lihle Mahamba,&nbsp;Mustafa Alhaji Isa,&nbsp;Abidemi Paul Kappo","doi":"10.1016/j.amolm.2025.100084","DOIUrl":"10.1016/j.amolm.2025.100084","url":null,"abstract":"<div><div><em>Human schistosomiasis</em> is a debilitating, neglected tropical disease affecting millions worldwide. Control efforts primarily rely on health education, improved sanitation, snail host management, and mass drug administration with Praziquantel (PZQ). PZQ has some limitations, such as its lower effectiveness against immature parasites and the potential for developing resistance. This requires the urgent need for new treatment approaches. The universal stress protein G4LZI3 helps the <em>Schistosoma mansoni</em> parasite survive when it is under stress from its host. Because of this, it emerges as a promising target for developing new drugs. Despite its biological relevance, G4LZI3 has not been previously investigated as a druggable target, highlighting a significant research gap in schistosomiasis drug discovery. To find potential inhibitors of G4LZI3, we conducted a virtual screening using the RASPD⁺ tool, which led us to select 7889 ligands from the CoCoNut database. These ligands were filtered based on physicochemical properties (Lipinski's Rule of Five, Veber's Rule, Egan's Filter, and the Ghose filter), pharmacokinetics, and Pan-Assay Interference Structures (PAINS) criteria, followed by molecular docking. Fifteen compounds demonstrated strong binding affinities, with binding energies ranging from −10.6 to −8.50 kcal/mol, exceeding that of PZQ (−8.4 kcal/mol). From these, six compounds were selected for further analysis, including molecular dynamics (MD) simulation, solvent-accessible surface area (SASA), and molecular mechanics generalized Born surface area (MM-GBSA) calculations. MD simulation of 200 ns revealed that CNP0475438, CNP0415153, and CNP0353858 achieved significant stability and favourable interactions with G4LZI3. These findings show these compounds as promising candidates for <em>S. mansoni</em> inhibition, pending experimental validation. The results identify novel scaffolds with vigorous predicted activity and provide a rational starting point for experimental optimization and development of new antiparasitic therapies that address praziquantel resistance and efficacy limitations in endemic regions.</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143900077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of antioxidants in skin aging and the molecular mechanism of ROS: A comprehensive review","authors":"Narmin Hama amin Hussen ,&nbsp;Sakar Karem Abdulla ,&nbsp;Naza Mohammed Ali ,&nbsp;Van Abdulqader Ahmed ,&nbsp;Aso Hameed Hasan ,&nbsp;Eman Erfan Qadir","doi":"10.1016/j.amolm.2025.100063","DOIUrl":"10.1016/j.amolm.2025.100063","url":null,"abstract":"<div><div>Skin aging is a multifaceted and gradual process influenced by both internal and external factors, including environmental stressors. These two mechanisms contribute to oxidative stress, triggered by ROS, which accelerates the aging of the skin. UV exposure increases the production of ROS in cells, which collectively contribute to the various skin changes linked to aging. However, the skin has a sophisticated antioxidant defense system that shields it from oxidative damage caused by both internal and external factors. The use of topical antioxidants have been shown to shield the skin from harmful free radicals generated intrinsically by regular cellular metabolism or as a result of UV light exposure. This review focuses on the assessment of the injury environmental factors cause to the skin, molecular mechanism of ROS in the skin aging, and the use of antioxidants to prevent that damaging and producing a protection against UV radiation from environmental factors. The systematic search was done for eligible articles which including in vivo and in vitro studies from studies between (1997 until 2024).</div></div>","PeriodicalId":72320,"journal":{"name":"Aspects of molecular medicine","volume":"5 ","pages":"Article 100063"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}